| 货号 | 11952-10mg |
| 描述 | Angiotensin II receptor blockers (ARBs) act as cardioprotective agents that are effective in hypertension, left ventricular hypertrophy, postmyocardial infarction, and heart failure.1 Irbesartan is an ARB with a high affinity for the AT1 receptor (Ki = 2.7 nM) and exceptionally high bioavailability (60-80%).2,3 It is an insurmountable antagonist of AT1, as its antagonism of this receptor cannot be overcome by increasing concentrations of angiotensin II.4 Irbesartan effectively reduces blood pressure alone but may also be used in combination with a diuretic, such as hydrochlorothiazide.3,5 As angiotensin II contributes in diverse ways to endothelial dysfunction, irbesartan and other ARBs directly protect the vascular endothelium.6,7 Other pathologies, including diabetes and kidney disease, also benefit from the cardiovascular and endothelial protective actions of ARBs like irbesartan.1,8 |
| 别名 | Aprovel;BMS 186295;Karvea;SR 47436; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Munger, M.A. Use of angiotensin receptor blockers in cardiovascular protection: Current evidence and future directions. PT 36(1), 22-40 (2011). 2.Burnier, M. Angiotensin II type 1 receptor blockers. Circulation 103, 904-912 (2001). 3.Asmar, R. Targeting effective blood pressure control with angiotensin receptor blockers. International Journal of Clinical Practice 60(3), 315-320 (2006). 4.Gradman, A.H. AT1-receptor blockers: Differences that matter. Journal of Human Hypertension 16, S9-S16 (2002). 5.Flack, J.M. Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: Focus on irbesartan/hydrochlorothiazide. International Journal of Clinical Practice 61(12), 2093-2102 (2007). 6.Negro, R. Endothelial effects of antihypertensive treatment: Focus on irbesartan. Vascular Health and Risk Management 4(1), 89-101 (2008). 7.Ikejima, H.,Imanishi, T.,Tsujioka, H., et al. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferation-activated receptor- g -modulating activity, on nitric oxide bioavailability and atherosclerotic change. Journal of Hypertension 26, 964-972 (2008). 8.Schmieder, R.E.,Martin, S.,Lang, G.E., et al. Angiotensin blockade to reduce microvascular damage in diabetes mellitus. Dtsch.Arztebl.Int. 106(34-35), 556-562 (2009). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 428.5 |
| 分子式 | C25H28N6O |
| CAS号 | 138402-11-6 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |